Skip to content
value.today
Exagen Diagnostics Inc. logo

Exagen Diagnostics Inc.

Total raised
$69 M
11 rounds on record
Latest round
$7 M
Jan 2019
First round on record
May 2009
Today
Went public
See the company page

Exagen Diagnostics Inc. is listed today as Exagen Inc.: market value, financials and filings are on its company page.

Funding rounds

11 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Exagen Diagnostics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$7 MNo. 11$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 11, Jan 2019

Investors in this round

4 investors had bought by the notice of Feb 1, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $16 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Kamal L.L. Adawi · Executive Officer
  • Thierry L.L. Dervieux · Executive Officer
  • Arthur L.L. Weinstein · Director
  • Brian R. Birk · Director
  • Daniel C. Burrell · Director
  • Ebetuel R. Pallares · Director
  • James L.L. Tullis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kamal Adawi, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 1, 2019. Read the notice at the SEC.

equitySEC
May 2017$4 MNo. 10$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 10, May 2017

Investors in this round

4 investors had bought by the notice of May 18, 2017: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $13 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Mark L.L. Hazeltine · Executive Officer
  • Thierry L.L. Dervieux · Executive Officer
  • Arthur L.L. Weinstein · Director
  • Brian R. Birk · Director
  • Ebetuel R. Pallares · Director
  • Frank M. Witney · Director
  • James L.L. Tullis · Director
  • John M. Radak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Hazeltine, Interim Chief Financial Officer. Source: SEC Form D, newest notice filed May 18, 2017. Read the notice at the SEC.

equitySEC
Jan 2016$17 MNo. 9$10 to $50 million

Exagen Diagnostics Inc.: Raise no. 9, Jan 2016

Investors in this round

13 investors had bought by the notice of Jan 26, 2016: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $31 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Thierry L.L. Dervieux · Executive Officer
  • Wendy R. Swedick · Executive Officer
  • Arthur L.L. Weinstein · Director
  • Brian R. Birk · Director
  • Ebetuel R. Pallares · Director
  • Frank M. Witney · Director
  • James L.L. Tullis · Director
  • John M. Radak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 26, 2016. Read the notice at the SEC.

equitySEC
Oct 2015$3 MNo. 8$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 8, Oct 2015

Investors in this round

4 investors had bought by the notice of Oct 21, 2015: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Thierry L.L. Dervieux · Executive Officer
  • Wendy R. Swedick · Executive Officer
  • Arthur L.L. Weinstein · Director
  • Brian R. Birk · Director
  • Ebetuel R. Pallares · Director
  • Frank M. Witney · Director
  • James L.L. Tullis · Director
  • John M. Radak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2015. Read the notice at the SEC.

debt, optionsSEC
Oct 2013$5 MNo. 7$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 7, Oct 2013

Investors in this round

11 investors had bought by the notice of Oct 15, 2013: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$900,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Thierry R. Dervieux · Executive Officer
  • Wendy R. Swedick · Executive Officer
  • Beto R. Pallares · Director
  • Brian R. Birk · Director
  • Curt R. LaBelle · Director
  • Michael R. Walsh · Director
  • Sam R. Riccitelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC.

equitySEC
Sep 2012$5 MNo. 6$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 6, Sep 2012

Investors in this round

7 investors had bought by the notice of Sep 11, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$530,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Thierry R. Dervieux · Executive Officer
  • Wendy R. Swedick · Executive Officer
  • Brian R. Birk · Director
  • Curt J. LaBelle · Director
  • David R. Blivin · Director
  • Michael J. Walsh · Director
  • Sam R. Riccitelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 11, 2012. Read the notice at the SEC.

equitySEC
Dec 2011$12 MNo. 5$10 to $50 million

Exagen Diagnostics Inc.: Raise no. 5, Dec 2011

Investors in this round

9 investors had bought by the notice of Dec 22, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $25 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fortunato R. Rocca · Executive Officer, Director
  • Thierry R. Dervieux · Executive Officer
  • Wendy R. Swedick · Executive Officer
  • Brian R. Birk · Director
  • Curtis J. LaBelle · Director
  • David R. Blivin · Director
  • Dinesh R. Patel · Director
  • Michael J. Walsh · Director
  • Sam R. Riccitelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 22, 2011. Read the notice at the SEC.

equitySEC
Sep 2011$5 MNo. 4$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 4, Sep 2011

Investors in this round

8 investors had bought by the notice of Sep 27, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$350,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott L. Glenn · Executive Officer, Director
  • Thierry J. Dervieux · Executive Officer
  • Wendy J. Swedick · Executive Officer
  • Brian L. Birk · Director
  • Curtis J. LaBelle · Director
  • David J. Bilvin · Director
  • Dinesh L. Patel · Director
  • Michael J. Walsh · Director
  • Stephanie L. Spong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 27, 2011. Read the notice at the SEC.

equity, debtSEC
Jun 2011$5 MNo. 3$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 3, Jun 2011

Investors in this round

8 investors had bought by the notice of Jun 29, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$460,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott L. Glenn · Executive Officer, Director
  • Thierry J. Dervieux · Executive Officer
  • Wendy L. Swedick · Executive Officer
  • Brian L. Birk · Director
  • Curtis J. LaBelle · Director
  • David J. Blivin · Director
  • Dinesh L. Patel · Director
  • Michael J. Walsh · Director
  • Stephanie L. Spong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 29, 2011. Read the notice at the SEC.

equity, optionsSEC
Oct 2010$5 MNo. 2$2 to $10 million

Exagen Diagnostics Inc.: Raise no. 2, Oct 2010

Investors in this round

17 investors had bought by the notice of May 11, 2011: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$550,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott L. Glenn · Executive Officer, Director
  • Wendy L. Swedick · Executive Officer
  • Brian L. Birk · Director
  • Dinesh L. Patel · Director
  • Michael J. Walsh · Director
  • Stephanie L. Spong · Director
  • Waneta C. Tuttle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 11, 2011. Read the notice at the SEC.

equity, debt, optionsSEC
May 2009$1 MNo. 1Under $2 million

Exagen Diagnostics Inc.: Raise no. 1, May 2009

Investors in this round

15 investors had bought by the notice of May 26, 2009: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$340,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in De

People named in the notice

  • John P. Alsobrook, II · Executive Officer
  • Lisa Davis · Executive Officer
  • Brian Birk · Director
  • Dinesh Patel · Director
  • John Bessone · Director
  • Todd Stevens · Director
  • Waneta C. Tuttle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John P. Alsobrook, II, President and CEO. Source: SEC Form D, newest notice filed May 26, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Exagen Inc., its revenue in fiscal 2025 came from these business segments: Reportable $66.58 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Exagen Diagnostics Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2009; revenue between $1 million and $5 million in 2011; revenue between $1 million and $5 million in 2012; revenue between $5 million and $25 million in 2013.

    SEC Form D (revenue range) · Oct 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2019

Products and services#

No products or services of Exagen Diagnostics Inc. are on record.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Exagen Diagnostics Inc.
InvestorKindAmountRoundRoleSource
H.I.G. Bio-Exagen, L.P.Fund or asset managernot statednot statedHeld Series H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
H.I.G.-GPII, Inc.Companynot statednot statedHeld Series H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Hunt Guaranty Inc.Companynot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Hunt Holdings Limited PartnershipFund or asset managernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
HuntVest, LLCOthernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
James L. L. TullisPersonnot statednot statedHeld Series F and H preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
NMSIC Co-Investment Fund, L.P.Fund or asset managernot statednot statedHeld Series A-3, C, D, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
NMSIC Focused LLCOthernot statednot statedHeld Series A-3, C, D, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sun Mountain Capital Partners LLCFund or asset managernot statednot statedHeld Series A-3, C, D, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Tullis Dickerson Capital Focus III, L.P.Fund or asset managernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Tullis Dickerson Partners III, L.L.C.Fund or asset managernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Tullis Growth Fund II, L.P.Fund or asset managernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Tullis Growth Fund, L.P.Fund or asset managernot statednot statedHeld Series A-3, C, E, F and H preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 11 rounds above had up to 17 investors.

Largest shareholders today

Institutions holding Exagen Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Exagen Diagnostics Inc.
NameRoleNamed in
Fortunato R. RoccaExecutive officerFeb 2019
Kamal L.L. AdawiExecutive officerFeb 2019
Thierry L.L. DervieuxExecutive officerFeb 2019
Mark L.L. HazeltineExecutive officerMay 2017
Wendy R. SwedickExecutive officerJan 2016
Thierry R. DervieuxExecutive officerOct 2013
Scott L. GlennExecutive officerSep 2011
Thierry J. DervieuxExecutive officerSep 2011
Wendy J. SwedickExecutive officerSep 2011
Wendy L. SwedickExecutive officerJun 2011
John P. Alsobrook, IIExecutive officerMay 2009
Lisa DavisExecutive officerMay 2009
Arthur L.L. WeinsteinDirectorFeb 2019
Brian R. BirkDirectorFeb 2019
Daniel C. BurrellDirectorFeb 2019
Ebetuel R. PallaresDirectorFeb 2019
Fortunato R. RoccaDirectorFeb 2019
James L.L. TullisDirectorFeb 2019
Frank M. WitneyDirectorMay 2017
John M. RadakDirectorMay 2017
Beto R. PallaresDirectorOct 2013
Curt R. LaBelleDirectorOct 2013
Michael R. WalshDirectorOct 2013
Sam R. RiccitelliDirectorOct 2013
Curt J. LaBelleDirectorSep 2012
David R. BlivinDirectorSep 2012
Michael J. WalshDirectorSep 2012
Curtis J. LaBelleDirectorDec 2011
Dinesh R. PatelDirectorDec 2011
Brian L. BirkDirectorSep 2011
David J. BilvinDirectorSep 2011
Dinesh L. PatelDirectorSep 2011
Scott L. GlennDirectorSep 2011
Stephanie L. SpongDirectorSep 2011
David J. BlivinDirectorJun 2011
Waneta C. TuttleDirectorMay 2011
Brian BirkDirectorMay 2009
Dinesh PatelDirectorMay 2009
John BessoneDirectorMay 2009
Todd StevensDirectorMay 2009

About

Clinical laboratory company.

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.